JP2021511060A5 - - Google Patents
Info
- Publication number
- JP2021511060A5 JP2021511060A5 JP2020540432A JP2020540432A JP2021511060A5 JP 2021511060 A5 JP2021511060 A5 JP 2021511060A5 JP 2020540432 A JP2020540432 A JP 2020540432A JP 2020540432 A JP2020540432 A JP 2020540432A JP 2021511060 A5 JP2021511060 A5 JP 2021511060A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant oncolytic
- oncolytic virus
- protein
- proteins
- virus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000160A JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622547P | 2018-01-26 | 2018-01-26 | |
| US62/622,547 | 2018-01-26 | ||
| PCT/US2019/015434 WO2019148109A1 (en) | 2018-01-26 | 2019-01-28 | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000160A Division JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021511060A JP2021511060A (ja) | 2021-05-06 |
| JP2021511060A5 true JP2021511060A5 (https=) | 2022-02-24 |
Family
ID=67396217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540432A Pending JP2021511060A (ja) | 2018-01-26 | 2019-01-28 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
| JP2024000160A Pending JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000160A Pending JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11786569B2 (https=) |
| EP (1) | EP3720283A4 (https=) |
| JP (2) | JP2021511060A (https=) |
| KR (1) | KR102849901B1 (https=) |
| CN (1) | CN111655845A (https=) |
| AU (1) | AU2019212840B2 (https=) |
| CA (1) | CA3087044A1 (https=) |
| WO (1) | WO2019148109A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP2023539195A (ja) * | 2020-08-27 | 2023-09-13 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用 |
| TW202227621A (zh) * | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| CN116286911A (zh) * | 2022-10-21 | 2023-06-23 | 上海鑫湾生物科技有限公司 | 一种响应缺氧环境调控病毒复制的可剪接系统及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4845327B2 (ja) * | 2000-07-21 | 2011-12-28 | 千葉県 | 腫瘍特異的プロモーター |
| US8969291B2 (en) * | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| HRP20150360T1 (hr) * | 2007-11-19 | 2015-05-08 | Transgene Sa | Poksvirusni onkolitiäśki vektori |
| CA2709292A1 (en) | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| WO2017043815A1 (en) * | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
| KR102016128B1 (ko) * | 2015-09-21 | 2019-08-29 | 주식회사 엘지화학 | 이차전지용 전극의 제조 방법 및 이에 따라 제조된 이차전지용 전극 |
-
2019
- 2019-01-28 WO PCT/US2019/015434 patent/WO2019148109A1/en not_active Ceased
- 2019-01-28 CA CA3087044A patent/CA3087044A1/en active Pending
- 2019-01-28 US US16/959,025 patent/US11786569B2/en active Active
- 2019-01-28 CN CN201980010099.4A patent/CN111655845A/zh active Pending
- 2019-01-28 EP EP19744411.0A patent/EP3720283A4/en active Pending
- 2019-01-28 KR KR1020207020696A patent/KR102849901B1/ko active Active
- 2019-01-28 AU AU2019212840A patent/AU2019212840B2/en active Active
- 2019-01-28 JP JP2020540432A patent/JP2021511060A/ja active Pending
-
2024
- 2024-01-04 JP JP2024000160A patent/JP2024029176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511060A5 (https=) | ||
| JP7514231B2 (ja) | 癌を治療するためのプラスミド構築体および使用方法 | |
| JP7447232B2 (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JP2021118723A5 (https=) | ||
| Murtaugh et al. | Inflammatory cytokines in animal health and disease | |
| JP2018514199A5 (https=) | ||
| Zou et al. | Functional characterisation of the recombinant tumor necrosis factors in rainbow trout, Oncorhynchus mykiss | |
| Putoczki et al. | IL-11 signaling as a therapeutic target for cancer | |
| US7141651B2 (en) | Multiple cytokine protein complexes | |
| Gafner et al. | An engineered antibody–interleukin‐12 fusion protein with enhanced tumor vascular targeting properties | |
| JP2018528774A5 (https=) | ||
| JP2021500932A5 (https=) | ||
| Shimizu et al. | Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction | |
| RU2005119305A (ru) | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 | |
| JP2019530440A5 (https=) | ||
| CN112426438A (zh) | 用于调控酸性环境免疫应答的组合物、其制备方法和用途 | |
| RU2015148920A (ru) | Расширенная адоптивная клеточная терапия | |
| IL295724A (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2021514661A5 (https=) | ||
| Sanchez et al. | Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8 | |
| US12552849B2 (en) | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof | |
| Westermann et al. | CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity | |
| JP2023542539A5 (https=) | ||
| Kukita et al. | Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system | |
| JP7827646B2 (ja) | がん免疫療法に対する応答性を決定する方法 |